Bone Biologics Corp Stock Debt To Equity
| BBLGW Stock | USD 20.20 0.00 0.00% |
Bone Biologics Corp fundamentals help investors to digest information that contributes to Bone Biologics' financial success or failures. It also enables traders to predict the movement of Bone Stock. The fundamental analysis module provides a way to measure Bone Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bone Biologics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | (0.77) | (0.81) |
Bone | Debt To Equity |
Bone Biologics Corp Company Debt To Equity Analysis
Bone Biologics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Bone Biologics Debt To Equity | -0.81 |
Most of Bone Biologics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bone Biologics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bone Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Bone Biologics is extremely important. It helps to project a fair market value of Bone Stock properly, considering its historical fundamentals such as Debt To Equity. Since Bone Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bone Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bone Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Bone Liabilities And Stockholders Equity
Liabilities And Stockholders Equity |
|
At this time, Bone Biologics' Liabilities And Stockholders Equity is fairly stable compared to the past year.
Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Bone Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bone Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bone Biologics' managers, analysts, and investors.Environmental | Governance | Social |
Bone Fundamentals
| Return On Equity | -1.09 | ||||
| Return On Asset | -0.53 | ||||
| Number Of Shares Shorted | 197 | ||||
| EBITDA | (4.22 M) | ||||
| Net Income | (4.11 M) | ||||
| Cash And Equivalents | 4.44 K | ||||
| Total Debt | 377.71 K | ||||
| Book Value Per Share | 1.81 X | ||||
| Cash Flow From Operations | (4.12 M) | ||||
| Earnings Per Share | (0.14) X | ||||
| Beta | 0.82 | ||||
| Total Asset | 3.86 M | ||||
| Retained Earnings | (85.02 M) | ||||
| Working Capital | 2.91 M | ||||
| Net Asset | 3.86 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.